Marvel Biosciences Corp · TSXV:MRVL

Marvel Biosciences — Investor Presentation (April 2022)

31 slides from Marvel Biosciences's investor presentation, April 2022

  1. Slide 1: Corporate Presentation – April 2022

    Corporate Presentation – April 2022 MRVL - TSXV www.marvelbiotechnology.com

  2. Slide 2: Disclaimer

    Disclaimer This corporate presentation and the information contained herein (the “Presentation”) is proprietary and for authorized use only. It is being provided for the use of prospective investors with the express understanding that, without the prior permission in writing from Marvel Biosciences

  3. Slide 3: Life sciences company developing synthetic derivatives of proven drugs

    We are a life sciences company whose primary focus is the discovery and the development of a synthetic derivative compound of a known proven drug. Our business model capitalizes on significantly lower cost, less time and a lower risk profile to bring a drug asset to commercialization faster than the

  4. Slide 4: Redevelopment of Off Patented Drugs: De-Risking the Science

    Redevelopment of Off Patented Drugs: De-Risking the Science Successfully Redeveloped Drugs: Drug development model: Thalidomide to Revlimid(>$1.3Bin sales) • New, patented versions of safe drugs are made to enhance activity for new diseases • Reduces risk, costs and development timelines morning sic

  5. Slide 5: Marvel's Lead Asset MB-204 is a Re-Developed Derivative of Istradefylline

    Marvel’s Lead Asset MB-204 is a Re-Developed Derivative of Istradefylline for: Depression and Alzheimer’s Disease Non-Alcoholic Steatohepatitis (Fatty liver disease)

  6. Slide 6: First In-Class Treatments Based on Re-Developing Istradefylline to MB-204

    First In-Class Treatments Based on Re-Developing Istradefylline to MB-204 Marvel is Redeveloping Istradefylline for Multiple Diseases MB-204 “Pipeline in a Product” for Multiple Diseases Istradefylline is only approved Adenosine A2a Antagonist for the treatment of Parkinson’s Disease. Similar to caf

  7. Slide 7: Redevelopment of Istradefylline to MB-204 – Effective & Longer Lasting

    Redevelopment of Istradefylline to MB-204 – Effective & Longer Lasting In Vitro IC50 Oral Pharmacokinetics Istradefylline MB-204 67 nM 75 nM Compound MB-204 Composition of matter patent filed March 2020 www.marvelbiotechnology.com

  8. Slide 8: MB-204 for Depression and Alzheimer's Disease – $30B market

    Marvel’s Lead Asset MB-204 is a Re-Developed Derivative of Istradefylline for: Depression and Alzheimer’s Disease – $30B market Non-Alcoholic Steatohepatitis (Fatty liver disease)

  9. Slide 9: Epidemic of Depression and Anxiety – Worse Than Ever

    Epidemic of Depression and Anxiety – Worse Tha n Ever DepressionRates by Age, 2009–2017 Pandemic Causes Spike in Anxiety & Depression % of U.S. adults showing symptomsof Anxietyand/ordepressivedisorder* Est. $30B market www.marvelbiotechnology.com

  10. Slide 10: What if there was a drug that could motivate you?

    The Need for New Anti-Depressants Selective Serotonin Reuptake Inhibitors (SSRIs) are the most prescribed anti-depressant drugs (e.g. Prozac), but take 2-4 weeks to work and up to 40% of users report apathy and a loss of motivation UP TO 40% APATHY / LOSS OF MOTIVATION What if there was a drug that

  11. Slide 11: First In-Class Anti-Depressant Based on Re-Developing Istradefylline

    First In-Class Anti-Depressant Based on Re-Developing Istradefylline Marvel’s first-in-class anti-depressant drug works via the dopamine pathway through a new target (the A2a receptor) to reduce Marvel is Redeveloping Istradefylline for Depression anxiety & apathy and increase motivation Dopamine Pa

  12. Slide 12: Lead Anti-Depressant Asset MB-204 – Safe and Highly Effective

    Lead Anti-Depressant Asset MB-204 (aka 1b) – Safe and Highly Effective Effective Safe Effective • Dosed orally 1 hr prior to test • Acute fast-acting effect ALT & AST are enzymes released Creatininereflects The forcedswim test is a key if the liver is injured kidneyhealth model of depression www.mar

  13. Slide 13: MB-204 for NASH (Fatty liver disease) – $20B market

    Marvel’s Lead Asset MB-204 is a Re-Developed Derivative of Istradefylline for: Depression and Alzheimer’s Disease Non-Alcoholic Steatohepatitis (Fatty liver disease) - $20B market

  14. Slide 14: Second Indication: Anti-Fibrotic Liver Treatment

    Second Indication: Anti-Fibrotic Liver Treatment The real danger of fatty liver disease is the development of fibrosis www.marvelbiotechnology.com

  15. Slide 15: Few Treatments for Liver Associated NASH Fibrosis

    Few Treatments for Liver Associated NASH Fibrosis Cenicriviroc is lead Phase 3 anti-fibrotic asset www.marvelbiotechnology.com

  16. Slide 16: Second Indication: Anti-Fibrotic Liver Treatment

    Second Indication: Anti-Fibrotic Liver Treatment Modulation of the Adenosine A2a Receptor decreases production of collagen which causes fibrosis MB-204 blocks signal www.marvelbiotechnology.com

  17. Slide 17: MB-204 First-in-Class Anti-Fibrotic for NASH using FDA Endpoints

    MB-204 First-in-Class Anti-Fibrotic for NASH using 2 FDA Endpoints Study 1: Study 2: Clinically Approved NAS Score Fibrosis Score vs Cenicriviroc (Phase 3) www.marvelbiotechnology.com

  18. Slide 18: MB-204 Potential Near Term Value Creation Events

    MB-204 Potential Near Term Value Creation Events Q2:2022 Q3:2022 Q4:2022 Q1:2023 H1:2023 Complete Complete MB-204 Begin Phase ½ clinical Pilot Phase ½ clinical Complete Phase ½ Formulation studies GLP toxicology trial of MB-204 trial results of MB-204 SAD/MAD clinical trial studies includes placebo

  19. Slide 19: Marvel's Second Program Involves Re-Development of Psilocybin

    Marvel’s Second Program Involves Re-Development of Psylocibin for: Depression Addiction

  20. Slide 20: Second Program: Safer Neuroplastic Promoting Drugs

    Second Program: Safer Neuroplastic Promoting Drugs Psychedelics with their neuroplastic effects have huge promise to treat a large number of brain related diseases but suffer from the potential for abuse (ketamine), can trigger hallucinations (LSD and tryptamines) and are typically given under medic

  21. Slide 21: Second Program: Next Iteration of the Psychedelic Space

    Second Program: Next Iteration of the Psychedelic Space www.marvelbiotechnology.com

  22. Slide 22: Second Program: Redeveloping Psilocybin

    Second Program: Redeveloping Psylocibin Psylocybin Novel patentable non-hallucinogenic psychoplastogen www.marvelbiotechnology.com

  23. Slide 23: Second Program: Safer Neuroplastic Promoting Drugs

    Second Program: Safer Neuroplastic Promoting Drugs Marvel has identified a set of molecules inspired by the tryptamine class of psychedelics that are: • Fast acting anti-depressants • Orally available • Water soluble • No evidence of hallucinations • Lead better than fluoxetine (Prozac, p<0.005) www

  24. Slide 24: Second Program: Next Steps

    Second Program: Next Steps Build out a library of Psylocibin derivatives (similar to Delix Therapeutics) by modifying R Confirm activity in: • In vitro neuritogenesis (neuroplasticity studies) • Mouse model of depression • Mouse model of addiction GOAL: to identify a novel candidate to be advanced t

  25. Slide 25: Stock & Financial Information

    Marvel Biosciences Corp. Stock & Financial Information Stock Information: • Shares outstanding: 32,586,231 • Insider Ownership: 12,525,098 (38.4%) • Warrant coverage: 10,071,533 • Stock options granted 2,825,000 Financial Information: • Cash: $859,175 (as at January 31, 2022) • Burn rate (estimated)

  26. Slide 26: Scientific Advisory Board

    Marvel Biosciences Corp. Scientific Advisory Board Dr. David Blum Dr. Blum adds crucial depth to the scientific board for his highly relevant research in the A2A receptor antagonists in cognition, brain lesions, and tau pathology for applications in Alzheimer's Disease (AD). Dr. Blum is a Senior Inv

  27. Slide 27: Management and Directors

    Marvel Biosciences Corp. Management and Directors Executive Management Rod Matheson : Chief Executive Officer and Director Dr. Mark Williams : President, Chief Science Officer and Director Harry Nijjar: Chief Financial Officer Independent Directors and Audit Committee Randy Smallbone Neil A. Johnson

  28. Slide 28: J. Roderick Matheson – Chief Executive Officer and Director

    J. Roderick Matheson – Chief Executive Officer and Director Mr. Matheson has spent over 35 years of his career in the investment and capital markets industries and is an experienced and seasoned senior executive in diverse areas of finance, capital markets, entrepreneurship and investing. Among his

  29. Slide 29: Neil A. Johnson - Director

    Neil A. Johnson - Director Mr. Johnson has over 25 years of experience in investment banking, merchant banking and research analysis in both the Canadian and UK capital markets. Mr. Johnson is presently, and has been since June 2015, Executive Director and Chief Executive Officer of Duke Royalty Ltd

  30. Slide 30: Contact Information

    Contact Information Rod Matheson rod@marvelbiosciences.com 403-770-2468 Dr. Mark Williams mark@marvelbiosciences.com 431-777-7759 Jacqueline Groot jackie@marvelbiosciences.com 403-770-2467 www.marvelbiotechnology.com

  31. Slide 31: Calgary office address and contact

    Suite 420, 505 8th Avenue S.W., Calgary, Alberta T2P 1G2 (403) 770-2469 : info@marvelbiosciences.com

Marvel Biosciences — Investor Presentation (April 2022) on 6ix